Type 2 diabetes and obesity dramatically increase the risk of dementia by up to 60%, accelerating amyloid pathology, cerebrovascular damage, and insulin resistance in the brain, sometimes described as type 3 diabetes [1]
Combination therapies Combination therapies that work via two mechanistically distinct targets to integrate immune modulation with a beta cell-specific component have been suggested [139,140,141] and encouraged [142]
That uncertainty should be making prescribers more cautious, not less
If you are transitioning from another GLP-1 medication, the timeline may differ slightly
Together, the four components create a synergistic environment that improves microcirculation, extracellular matrix remodeling, and overall tissue resilience